BioCardia Announces Completion Of Enrollment In Phase III CardiAMP HF Trial And Plans For CardiAMP HF Trial II
Portfolio Pulse from Benzinga Newsdesk
BioCardia, Inc. (NASDAQ:BCDA) has completed enrollment for its CardiAMP Heart Failure Trial and is initiating discussions with the FDA for a second pivotal study protocol. The aim of the second study is to gain FDA marketing approval.
October 11, 2023 | 10:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioCardia's completion of enrollment for its CardiAMP Heart Failure Trial and plans for a second study could potentially lead to FDA approval, which would be a significant milestone for the company.
The completion of enrollment for the CardiAMP Heart Failure Trial is a significant step for BioCardia. The initiation of discussions with the FDA for a second study indicates the company's progress and potential for gaining FDA approval. This could have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100